NYMC Faculty Publications
Clearance of FGF-23 During Continuous Renal Replacement Therapy
Journal Title
Hemodialysis International.International Symposium on Home Hemodialysis
First Page
366
Last Page
368
Document Type
Letter to the Editor
Publication Date
July 2019
Department
Medicine
Abstract
FGF-23 is a 32 kDa protein that is a key regulator of phosphorus and vitamin D metabolism. Emerging evidence also demonstrates that FGF-23 increases within 24 hours of acute kidney injury (AKI) and may be associated with adverse clinical outcomes. We conducted this study to evaluate FGF23 clearance during continuous veno-venous hemofiltration (CVVH) in critically ill patients with AKI. We demonstrate that plasma clearance of FGF-23 during CVVH is approximately 11 mL/min and the mean sieving coefficient is 0.27 +/- 0.1. Future studies will need to clarify FGF-23's role in adverse outcomes among AKI patients, and whether therapies aimed at reducing FGF-23 levels may be beneficial.
Recommended Citation
Sharma, S., Christov, M., Ix, J., & Waikar, S. (2019). Clearance of FGF-23 During Continuous Renal Replacement Therapy. Hemodialysis International.International Symposium on Home Hemodialysis, 23 (3), 366-368. https://doi.org/10.1111/hdi.12758
